Status:
RECRUITING
Efficacy and Safety of Short Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease
Lead Sponsor:
Genoss Co., Ltd.
Conditions:
Percutaneous Coronary Intervention
Dual Antiplatelet Therapy
Eligibility:
All Genders
19+ years
Brief Summary
The objective of study is to evaluate the efficacy and safety of short duration of DAPT after GENOSS® DES Implantation in patients with coronary artery disease.
Detailed Description
The Genoss DES is a novel, biodegradable, polymer-coated, sirolimus eluting stent with a cobalt-chromium stent platform and thin strut. Although the efficacy and safety of this stent have been previou...
Eligibility Criteria
Inclusion
- Patients of 19 and over
- Patients with coronary artery disease treated with GENOSS SES
- Participants who voluntarily decide to participate in this clinical trial, agree to the study protocol and clinical follow-up plan, and provide written informed consent as study participants
Exclusion
- Patients with cardiogenic shock at the time of hospitalization
- Patients who are pregnant or planning to become pregnant
- Patients with a life expectancy of less than 1 year
- Patients participating in randomized controlled trials using other medical devices
- Patients who have already received treatment with another DES (Drug Eluting Stent) or BMS (Bare Metal Stent) at the time of registration (However, other stent insertions are allowed due to failure of GENOSS DES insertion)
Key Trial Info
Start Date :
August 18 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06075420
Start Date
August 18 2021
End Date
December 31 2027
Last Update
February 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wonju Severance Christian Hospital
Wŏnju, Gangwon State, South Korea